These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33847688)

  • 1. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
    Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
    Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
    Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive anaplastic large cell lymphoma: A single institutional experience.
    He Y; Pei K; Zhang H; Wang J; Su X; Gan W; Wang P
    Cancer Med; 2023 Mar; 12(6):7182-7188. PubMed ID: 36408869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
    Brugières L; Cozic N; Houot R; Rigaud C; Sibon D; Arfi-Rouche J; Bories P; Cottereau AS; Delmer A; Ducassou S; Garnier N; Lamant L; Leruste A; Millot F; Moalla S; Morschhauser F; Nolla M; Pagnier A; Reguerre Y; Renaud L; Schmitt A; Simonin M; Verschuur A; Hoog Labouret N; Mahier Ait Oukhatar C; Vassal G
    Eur J Cancer; 2023 Sep; 191():112984. PubMed ID: 37549532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.
    Sun X; Fang X; Jiang Y
    Indian J Cancer; 2021; 58(1):108-111. PubMed ID: 33402581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
    Cleary JM; Rodig S; Barr PM; Shinagare AB; Clark JW; Shapiro GI; Armand P
    J Natl Compr Canc Netw; 2014 Mar; 12(3):323-6; quiz 326. PubMed ID: 24616538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report.
    Harrer DC; Menhart K; Mayer S; Herr W; Reichle A; Vogelhuber M
    Front Oncol; 2020; 10():585830. PubMed ID: 33134180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
    Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
    Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
    Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D; Koh Y; Yoon SS
    Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
    Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
    J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
    Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
    J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.